Hypertrophic cardiomyopathy is a common inherited heart disease with serious adverse outcomes such as arrhythmias, sudden cardiac death and heart failure. Hypertrophic cardiomyopathy is caused due to the mutation or changes in one or more genes, which is inherited. Further, chest pain, fainting & light headaches, and palpitations, are some of the major symptoms of hypertrophic cardiomyopathy. Further, Hypertrophic cardiomyopathy enabled the development of mouse models that reiterate clinical manifestations of disease. In addition, these models provide unforeseen insight into the chemical and biological properties and which may help to improve clinical diagnosis and management of patient with Hypertrophic cardiomyopathy therapeutics. According to American Heart Association (AHA), in March 2016, hypertrophic cardiomyopathy affects around 500,000 people in the U.S. annually.
Increasing prevalence of chronic cardiovascular diseases which is expected to increase the growth of hypertrophic cardiomyopathy therapeutics market. In addition, there are various invasive therapy such as septal reduction therapy and heart transplantation which are used against symptomatic patients and this is anticipated to boost the growth of hypertrophic cardiomyopathy therapeutics. Further, according to the FDA, only propranolol carries an on-label indication for hypertrophic cardiomyopathy but on the other hand, there are some drugs in clinical pipelines such as mavacamten, to be used in obstructive hypertrophic, symptomatic, cardiomyopathy and this is anticipated to increase the demand for hypertrophic cardiomyopathy therapeutics in near future. Furthermore, market is expected to gain significant growth from government interventions and spreading awareness about hypertrophic cardiomyopathy.
However, due to increase in the technological upgradation in devices such as defibrillators and pacemakers are anticipated to hamper the growth of hypertrophic cardiomyopathy therapeutics market.
Rapid increase in corona virus all around the world is expected to hamper the growth of hypertrophic cardiomyopathy therapeutics market. The virus outburst has become one of the threats to the global economy and financial markets. The impact has made immense decrease in revenue generation in the field of all healthcare industry growth for the market in terms of compatibility and it has led in huge financial losses and human life which has hit very hard to the core of developing as well as emerging economies in healthcare sector. It further anticipated that such gloomy epidemiological pandemic environment is going to remain in next for at least some months, and this is going to also affect the life-science market which also include the market of hypertrophic cardiomyopathy therapeutics market.
The global hypertrophic cardiomyopathy therapeutics market is segmented based on Disease Type, Drug Class, End User and Geography:
Based on the Disease Type, hypertrophic cardiomyopathy therapeutics market is segmented into
Based on the Drug Class, hypertrophic cardiomyopathy therapeutics market is segmented into:
Based on the End User, hypertrophic cardiomyopathy therapeutics market is segmented into:
Based on the disease type, obstructive hypertrophic cardiomyopathy is expected to dominate the market due to increase in the prevalence of cardiovascular diseases. Further, based on the drug type, calcium channel blockers are anticipated to increase the demand for hypertrophic cardiomyopathy therapeutics. This is due to calcium channel blockers provides an efficient substitute to beta-blocker therapy mainly used in obstructive hypertrophic cardiomyopathy treatment. Furthermore, based on the end user, hospitals segment is expected to spur the market growth due to increase in the number of chronic diseases.
Geographically, the global hypertrophic cardiomyopathy therapeutics market is segmented into regions such as Latin America, Europe, North America, South Asia, East Asia Middle East & Africa and Oceania. North America is projected to emerge as prominent market in the global hypertrophic cardiomyopathy therapeutics market due to increasing inclination towards a sedentary lifestyle. Europe is the second leading region to dominate the market due to increasing prevalence of obesity among the younger population. For instance, in 2017, according to the European Cardiovascular Disease Statistics, the obesity rates are high across the both Europe and EU, including the both adults and children. Asia pacific is expected to show significant growth due to awareness regarding hypertrophic cardiomyopathy therapeutics.
Some of the major key players competing in the global hypertrophic cardiomyopathy therapeutics market are Pfizer, Inc., Merck & Co Company, Sanofi S.A., Mylan N. V. Teva Pharmaceuticals Limited and others.
The report covers exhaustive analysis on:
Competition & Companies involved
Hypertrophic cardiomyopathy therapeutics Market Drivers and Restraints
Historical, current and projected industry size Recent industry trends
Key Competition landscape